The company is responsible for much of the interior work in both private and public jets. Due to the strong backlog for plane manufacturers, shares of BEAV have been "up, up, up!" he exclaimed.
B/E Aerospace cancelled its analyst meeting originally scheduled for today, announcing that is exploring a potential sale, merger or split up, Cramer added. Although some analysts are calling shares of BEAV overvalued, Cramer disagreed, arguing, "This company is worth a great deal."
So who would buy the company?
Turning to Pfizer (PFE), Cramer was not impressed by its earnings results. He added that AstraZeneca (AZN) -- the company Pfizer wants to buy -- does not have as strong a cancer pipeline as initially thought.
He concluded that Merck (MRK) has a more "exciting story" than Pfizer, especially with its consumer products division.
-- Written by Bret Kenwell in Petoskey, Mich.